Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 31414

1.

The optimal time for surgery in women with serous ovarian cancer.

Stewart JM, Tone AA, Jiang H, Bernardini MQ, Ferguson S, Laframboise S, Murphy KJ, Rosen B, May T.

Can J Surg. 2016 Jun 1;59(4):14315. doi: 10.1503/cjs.014315. [Epub ahead of print]

PMID:
27240134
2.

Advances in ovarian cancer diagnosis: A journey from immunoassays to immunosensors.

Sharma S, Raghav R, O'Kennedy R, Srivastava S.

Enzyme Microb Technol. 2016 Jul;89:15-30. doi: 10.1016/j.enzmictec.2016.03.002. Epub 2016 Mar 11. Review.

PMID:
27233124
3.

A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib.

Takekuma M, Wong KK, Coleman RL.

Gynecol Oncol Res Pract. 2016 May 5;3:5. doi: 10.1186/s40661-016-0026-5. eCollection 2016.

PMID:
27231576
Free PMC Article
4.

Efficacy of Postoperative Hormone Replacement Therapy on Prognosis of Patients with Serous Ovarian Carcinoma.

Zhang YL, Chen JH, Lu W, Li BL, Zhu QY, Wan XP.

Chin Med J (Engl). 2016 5th Jun;129(11):1316-1321. doi: 10.4103/0366-6999.182835.

PMID:
27231169
5.

The role of early life exposures on subsequent cancer risk.

Wijnen M, van den Heuvel-Eibrink MM, Medici M, Peeters RP, Van der Lely A, Neggers S.

Endocr Relat Cancer. 2016 May 26. pii: ERC-16-0113. [Epub ahead of print]

PMID:
27229933
6.

Paired boxed gene 1 expression: A single potential biomarker for differentiating endometrial lesions associated with favorable outcomes in patients with endometrial carcinoma.

Liu LC, Lai HC, Chou YC, Huang RL, Yu MH, Lin CP, Tsai WC, Chiang KJ, Wang YC, Chao TK.

J Obstet Gynaecol Res. 2016 May 26. doi: 10.1111/jog.13040. [Epub ahead of print]

PMID:
27226215
7.

[Endometrial adenocarcinoma and clear cell carcinoma in a young woman with polycystic ovarian syndrome: a case report].

Niu J, Liu N, Liu GB.

Nan Fang Yi Ke Da Xue Xue Bao. 2016 May 20;36(5):733-4. Chinese.

PMID:
27222196
8.

Characteristics, treatment and outcomes of women with immature ovarian Teratoma, 1998-2012.

Jorge S, Jones NL, Chen L, Hou JY, Tergas AI, Burke WM, Ananth CV, Neugut AI, Herhshman DL, Wright JD.

Gynecol Oncol. 2016 May 21. pii: S0090-8258(16)30753-3. doi: 10.1016/j.ygyno.2016.05.024. [Epub ahead of print]

PMID:
27222024
9.

Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-grade Serous Carcinoma: A Review of the Evidence.

Sherman M, Drapkin R, Horowitz NS, Crum CP, Friedman S, Kwon J, Levine DA, Shih IM, Shoupe D, Swisher EM, Walker J, Trabert B, Greene MH, Samimi G, Temkin SM, Minasian L.

Cancer Prev Res (Phila). 2016 May 24. pii: canprevres.0384.2015. [Epub ahead of print]

PMID:
27221539
10.

Synaptotagmin-like protein 2 gene promotes the metastatic potential in ovarian cancer.

Sung HY, Han J, Ju W, Ahn JH.

Oncol Rep. 2016 May 24. doi: 10.3892/or.2016.4835. [Epub ahead of print]

PMID:
27220283
11.

Vaginal fine-needle aspiration: A useful alternative to biopsy.

Lin DM, Barkan GA, Chatt G, Park JW, Gattuso P.

Diagn Cytopathol. 2016 May 24. doi: 10.1002/dc.23504. [Epub ahead of print]

PMID:
27220040
12.

Squamous Cell Carcinoma Arising in Ovarian Teratoma: A Diagnostic Conundrum.

Sharma S, Gupta N, Rajwanshi A, Dhaliwal LK.

Indian J Surg Oncol. 2015 Sep;6(3):316-7. doi: 10.1007/s13193-015-0393-0. Epub 2015 Mar 11. No abstract available.

PMID:
27217690
13.

Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

Monk BJ, Sill MW, Walker JL, Darus CJ, Sutton G, Tewari KS, Martin LP, Schilder JM, Coleman RL, Balkissoon J, Aghajanian C.

J Clin Oncol. 2016 May 23. pii: JCO658153. [Epub ahead of print]

PMID:
27217446
14.

Down-regulation of SIRT3 promotes ovarian carcinoma metastasis.

Dong XC, Jing LM, Wang WX, Gao YX.

Biochem Biophys Res Commun. 2016 May 20. pii: S0006-291X(16)30806-3. doi: 10.1016/j.bbrc.2016.05.098. [Epub ahead of print]

PMID:
27216459
15.

A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome.

Reinartz S, Finkernagel F, Adhikary T, Rohnalter V, Schumann T, Schober Y, Nockher WA, Nist A, Stiewe T, Jansen JM, Wagner U, Müller-Brüsselbach S, Müller R.

Genome Biol. 2016 May 23;17(1):108. doi: 10.1186/s13059-016-0956-6.

16.

Design, Synthesis, and Evaluation of in Vitro and In Vivo Anticancer Activity of 4-Substituated Coumarins: A Novel Class of Potent Tubulin Polymerization Inhibitors.

Cao D, Liu Y, Yan W, Wang C, Bai P, Wang T, Tang M, Wang X, Yang Z, Ma B, Ma L, Lei L, Wang F, Xu B, Zhou Y, Yang T, Chen L.

J Med Chem. 2016 May 23. [Epub ahead of print]

PMID:
27213819
17.

Differential effects of rapalogues, dual kinase inhibitors on human ovarian carcinoma cells in vitro.

Rogers-Broadway KR, Chudasama D, Pados G, Tsolakidis D, Goumenou A, Hall M, Karteris E.

Int J Oncol. 2016 May 18. doi: 10.3892/ijo.2016.3531. [Epub ahead of print]

PMID:
27211906
18.

An uncommon manifestation of paraneoplastic cerebellar degeneration in a patient with high grade urothelial, carcinoma with squamous differentiation: A case report and literature review.

Zhu Y, Chen S, Chen S, Song J, Chen F, Guo H, Shang Z, Wang Y, Zhou C, Shi B.

BMC Cancer. 2016 May 21;16:324. doi: 10.1186/s12885-016-2349-3.

19.

Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.

Mignogna C, Staropoli N, Botta C, De Marco C, Rizzuto A, Morelli M, Di Cello A, Franco R, Camastra C, Presta I, Malara N, Salvino A, Tassone P, Tagliaferri P, Barni T, Donato G, Di Vito A.

J Ovarian Res. 2016 May 21;9(1):31. doi: 10.1186/s13048-016-0238-7.

20.

Posttreatment FDG PET/CT in predicting survival of patients with ovarian carcinoma.

Chu LC, Tsai HL, Wang H, Crandall J, Javadi MS, Wahl RL.

EJNMMI Res. 2016 Dec;6(1):42. doi: 10.1186/s13550-016-0194-7. Epub 2016 May 20.

PMID:
27206785
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk